Latest News Combining either oleclumab or monalizumab with durvalumab provided a progression-free survival benefit over durvalumab alone.
Adding elotuzumab to lenalidomide and dexamethasone did not improve any efficacy outcomes.
A DBT-based risk model can predict cancer after a negative screening exam, with high discriminative performance for one-year risk.
A team of researchers investigated the long-term effects of eliminating H pylori infection in patients at high risk for gastric cancer.
President Biden ordered U.S. flags to be flown at half-staff in honor of those lost.
A return to full stocking levels is expected by July 2022.
The intervention would yield a net monetary benefit of £10.6 million and a net health benefit of 530 QALYs, researchers found.
In the safety communication, the FDA noted that the use of this unauthorized test may increase the risk of false results.
A meta-analysis showed a significant improvement in overall survival, but not disease-free survival, with laparoscopic surgery.
There were no significant differences in outcomes between patients with low HER2 expression and those with no HER2 expression, after adjusting for hormone receptor status.
Cancer patients had higher risks for 30-day mortality and hospitalization.
The median time to definitive deterioration was longer with lenvatinib-pembrolizumab than with sunitinib.
Researchers sought to determine whether there were long-term benefits for patients with hematologic malignancies treated with allo-HSCT and omidubicel.
Nearly 400 million doses of vaccine made by Emergent were destroyed “due to poor quality control.”
The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.
Load More